GlassScriptPhysician profile
Mark H Hite
NPI 1366488025
$7,151.99
in general payments reported to CMS, 2019-2025
30 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $596 · 2021: $853 · 2022: $1,480 · 2023: $960 · 2024: $1,523 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.74 | 2022-2025 | |
| Alcon Vision LLC | $1,274.58 | 2019-2025 | Argos, Rocklatan, Clareon |
| Bausch & Lomb Americas INC. | $542.08 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $504.72 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $439.89 | 2019-2025 | |
| Sight Sciences, INC. | $369.77 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $367.98 | 2019-2021 | |
| Allergan, INC. | $362.06 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $243.92 | 2019-2020 | |
| Dompe US, INC. | $230.04 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $222.74 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $183.14 | 2021-2022 | |
| Astellas Pharma US INC | $174.86 | 2024-2025 | Izervay |
| Ocular Therapeutix, INC. | $159.00 | 2019-2025 | Dextenza |
| Spark Therapeutics, INC. | $143.42 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $104.26 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $104.00 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $67.02 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.22 | 2019-2020 | |
| Eyepoint US, INC. | $50.11 | 2019-2020 | |
| Rxsight INC | $46.87 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Omeros Corporation | $36.05 | 2019 | |
| Horizon Therapeutics Plc | $33.53 | 2019-2023 | Tepezza |
| Glaukos Corporation | $29.41 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.25 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Harrow Eye, LLC | $16.78 | 2024 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $16.44 | 2022 | |
| Mallinckrodt Enterprises LLC | $15.36 | 2019 | |
| Tearlab Corp | $14.31 | 2023 | Tearlab Osmolarity System |
| Optos, INC. | $6.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.